1. | No ocular trauma or surgery preceding onset of diseasea |
2. | Bilateral involvement (verified with ICGA and/or EDI-OCT)a |
3. | Exclusion of other infectious, inflammatory or masquerading entities, in particular other stromal choroiditis entities (i.e. tuberculosis, sarcoidosis or syphilis)a |
4. | Signs and symptoms of more than 4 weeks´ duration before treatment initiationa |
5. | Ocular depigmentation findings (i.e., sunset glow fundus, Sugiura sign, Dallen-Fuchs-like nodules) |
6. | Integumentary findings (i.e., vitiligo, poliosis) |
7. | Choroidal atrophy (evidenced by thinning and/or distortion of vascular architecture on EDI-OCT and/or ICG) |
8. | Treatment refractoriness, defined as absence of inflammatory improvement or persistence of inflammation (namely not achieving a two-step decrease in the level of inflammation or a decrease to grade 0 and/or persistence of retinal detachment), despite a minimum of 4 to 6 weeks of systemic therapy [105] |
9. | Presence of ocular complications, such as cataract, glaucoma, hypotony, choroidal neovascularization. |
10. | Presence of granulomatous anterior segment inflammation (namely Koeppe/Bussacca iris nodules plus mutton-fat keratic precipitates) [6, 44]. |